Supernus says ADHD drug trounces rivals, but shares slideSupernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, Share XSupernus says ADHD drug trounces rivals, but shares slidehttps://pharmaphorum.com/news/supernus-says-adhd-drug-trounces-rivals-but-shares-slide/
